172 related articles for article (PubMed ID: 23894097)
1. Strategic targeting of multiple water-mediated interactions: a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors.
Fischer T; Riedl R
ChemMedChem; 2013 Sep; 8(9):1457-61, 1572. PubMed ID: 23894097
[No Abstract] [Full Text] [Related]
2. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
Choi JY; Fuerst R; Knapinska AM; Taylor AB; Smith L; Cao X; Hart PJ; Fields GB; Roush WR
J Med Chem; 2017 Jul; 60(13):5816-5825. PubMed ID: 28653849
[TBL] [Abstract][Full Text] [Related]
4. Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain.
Kothapalli R; Khan AM; Basappa ; Gopalsamy A; Chong YS; Annamalai L
PLoS One; 2010 Aug; 5(8):e12494. PubMed ID: 20824169
[TBL] [Abstract][Full Text] [Related]
5. Drug Design Inspired by Nature: Crystallographic Detection of an Auto-Tailored Protease Inhibitor Template.
Gall FM; Hohl D; Frasson D; Wermelinger T; Mittl PRE; Sievers M; Riedl R
Angew Chem Int Ed Engl; 2019 Mar; 58(12):4051-4055. PubMed ID: 30615822
[TBL] [Abstract][Full Text] [Related]
6. Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8.
Kalva S; Vinod D; Saleena LM
J Mol Model; 2014 May; 20(5):2191. PubMed ID: 24756550
[TBL] [Abstract][Full Text] [Related]
7. Receptor-based 3D-QSAR approach to find selectivity features of flexible similar binding sites: case study on MMP-12/MMP-13.
Hadizadeh F; Shamsara J
Int J Bioinform Res Appl; 2015; 11(4):326-46. PubMed ID: 26561318
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
[TBL] [Abstract][Full Text] [Related]
9. Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
Spicer TP; Jiang J; Taylor AB; Choi JY; Hart PJ; Roush WR; Fields GB; Hodder PS; Minond D
J Med Chem; 2014 Nov; 57(22):9598-611. PubMed ID: 25330343
[TBL] [Abstract][Full Text] [Related]
10. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
Senn N; Ott M; Lanz J; Riedl R
J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
[TBL] [Abstract][Full Text] [Related]
11. Virtual High-Throughput Screening for Matrix Metalloproteinase Inhibitors.
Choi JY; Fuerst R
Methods Mol Biol; 2017; 1579():259-271. PubMed ID: 28299742
[TBL] [Abstract][Full Text] [Related]
12. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
Xie XW; Wan RZ; Liu ZP
ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
[TBL] [Abstract][Full Text] [Related]
13. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
14. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.
Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810
[TBL] [Abstract][Full Text] [Related]
15. In silico study combining docking and QSAR methods on a series of matrix metalloproteinase 13 inhibitors.
Xi L; Li S; Yao X; Wei Y; Li J; Liu H; Wu X
Arch Pharm (Weinheim); 2014 Nov; 347(11):825-33. PubMed ID: 25363411
[TBL] [Abstract][Full Text] [Related]
16. Molecular Recognition of the Catalytic Zinc(II) Ion in MMP-13: Structure-Based Evolution of an Allosteric Inhibitor to Dual Binding Mode Inhibitors with Improved Lipophilic Ligand Efficiencies.
Fischer T; Riedl R
Int J Mol Sci; 2016 Mar; 17(3):314. PubMed ID: 26938528
[TBL] [Abstract][Full Text] [Related]
17. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
[TBL] [Abstract][Full Text] [Related]
18. Merging allosteric and active site binding motifs: de novo generation of target selectivity and potency via natural-product-derived fragments.
Lanz J; Riedl R
ChemMedChem; 2015 Mar; 10(3):451-4. PubMed ID: 25487909
[TBL] [Abstract][Full Text] [Related]
19. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
Roth J; Minond D; Darout E; Liu Q; Lauer J; Hodder P; Fields GB; Roush WR
Bioorg Med Chem Lett; 2011 Dec; 21(23):7180-4. PubMed ID: 22018790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
